NCT02609776 2026-04-13CHRYSALISJanssen Research & Development, LLCPhase 1 Active not recruiting751 enrolled 2 FDA
NCT04077463 2026-04-13Chrysalis-2Janssen Research & Development, LLCPhase 1 Active not recruiting701 enrolled
NCT05388669 2026-04-13PALOMA-3Janssen Research & Development, LLCPhase 3 Active not recruiting418 enrolled 16 charts 1 FDA
NCT05663866 2026-04-13Premedication to Reduce Amivantamab Associated Infusion Related ReactionsJanssen Research & Development, LLCPhase 2 Active not recruiting68 enrolled 12 charts